trial

A Study of LY2140023 in Patients With Schizophrenia

NCTId NCT01307800
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 567 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
567 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-03
Primary completion
2012-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pomaglumetad

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

13 total
Wichita, United StatesGuadalajara, MexicoMonterrey, MexicoSan Juan, Puerto RicoLipetsk, RussiaMoscow, RussiaSaint Petersburg, RussiaSaratov, RussiaVoronezh, RussiaDonetsk, UkraineKiev, UkraineLviv, Ukraine

Linked catalysts

1
A Study of LY2140023 in Patients With Schizophrenia — primary completion2012-09

Facts & assertions

4 sourced
Enrollment
567
Phase
PHASE3
Primary Completion Date
2012-09
Status
TERMINATED
relationships
The graph out of here
drug
Pomaglumetad
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person